Integrin β6 (E4M9P) XP® Rabbit mAb (Alexa Fluor® 488 Conjugate) #28351
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | |
| Source/Isotype | Rabbit IgG |
Application Key:
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Description
Product Usage Information
| Application | Dilution |
|---|---|
| Immunohistochemistry (Paraffin) | 1:100 - 1:400 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
The avβ6 subunit was identified in epithelial cells and interacts with the fibronectin receptor integrin α5 (3,4). It is expressed during development, but expression becomes repressed in adulthood (5). It is involved in wound healing, fibrosis, pulmonary fibrosis in particular, and tumorigenesis (6-8). When the dimer is unregulated in the membrane in response to injury, the integrin β6 subunit binds directly to an RGD motif present in fibronectin and TGF-β, both present in the extracellular matrix. Integrin β6 cleaves and binds the LAP fragment of latent TGF-β, thereby releasing active TGF-β into the ECM to activate myofibroblasts, which consequently mediate ECM remodeling (6-8).
- Liu, S. et al. (2000) J Cell Sci 113 (Pt 20), 3563-71.
- Hood, J.D. and Cheresh, D.A. (2002) Nat Rev Cancer 2, 91-100.
- Breuss, J.M. et al. (1995) J Cell Sci 108 (Pt 6), 2241-51.
- Sheppard, D. et al. (1990) J Biol Chem 265, 11502-7.
- Busk, M. et al. (1992) J Biol Chem 267, 5790-6.
- Haapasalmi, K. et al. (1996) J Invest Dermatol 106, 42-8.
- Munger, J.S. et al. (1999) Cell 96, 319-28.
- Bandyopadhyay, A. and Raghavan, S. (2009) Curr Drug Targets 10, 645-52.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.